Orders from 1390 SEK Free delivery from 2895 SEK Ready for pickup dead drop: collect in 5 min Free parcel delivery from 2895 SEK

Substances · Cannabinoids (Indazole carboxamides)

ADB-PINACA

C19H28N4O2 CAS 1633766-73-0 Analytical reference material — not for human consumption
ADB-PINACA, educational illustration of the molecular structure
Educational illustration of the molecular structure. This is not a photograph of the product.
Preferred name
ADB-PINACA
IUPAC name
N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentylindazole-3-carboxamide
Parent CAS number (reference)
1633766-73-0
Molecular formula
C19H28N4O2
Molecular weight
344.5 g/mol
InChIKey
FWTARAXQGJRQKN-UHFFFAOYSA-N
PubChem
CID 86280478
Source
PubChem
Verified synonyms & catalog abbreviations
ADBPINACA ADB PINACA

Verified Neurochemical & Toxicological Intelligence

ADB-PINACA

Synthetic Cannabinoid Receptor Agonist (Sub-Nanomolar Full CB1/CB2 Agonist) Indazole-3-carboxamide (1-pentyl tert-leucinamide synthetic cannabinoid)
Verified PubChem & CAS Identity C19H28N4O2 · CAS 1633766-73-0 · CID 86280478
Calibrated Physical Form Pure Crystalline / Analytical Powder (≥98%)
≥98% Analytical Purity Verified 344.46 g/mol
Peer-Reviewed & Agency Citations 3 · verified sources

Receptor Telemetry & Mechanism of Action

CB₁ Central Cannabinoid Receptor Full Agonist (Sub-nM)
CB₂ Peripheral Cannabinoid Receptor Full Agonist

Sub-nanomolar **full agonist** at both human CB1 (**EC50 = 0.52 nM**) and CB2 receptors (**EC50 = 0.88 nM**) in FLIPR membrane potential assays (Banister et al., 2015, PMID 26134475). Extending the 1-alkyl tail from 4 carbons (ADB-BUTINACA, EC50 = 6.36–11.5 nM) to 5 carbons (ADB-PINACA, EC50 = 0.52 nM) increases CB1 potency >12-fold, matching 5F-MDMB-PINACA (0.59 nM). Linked in CDC emergency-medicine investigations (Schwartz et al., 2015, PMID 25726258) to outbreaks of severe delirium, aggression, anxiety, hospitalizations, and deaths.

Biotransformation & Active Metabolites

Human hepatocyte HRMS studies (Carlier et al., 2017) identified 19 major metabolites led by pentyl hydroxylation, ketone formation, ADB-PINACA pentanoic acid, and glucuronidation.

Temporal Pharmacokinetics

Ultra-potent, fast-onset full-CB1 intoxication that escalates across an unforgiving microgram margin from intense physical stone into severe confusion, anxiety, agitated delirium, or unconsciousness.

  1. Onset 1–3 minutes inhaled
  2. Peak Window 10–30 minutes inhaled
  3. Total Window 1–2.5 hours inhaled (class estimate; clinical delirium hospitalizations lasted hours longer)
  4. Residual / Half-Life 2–8 hours of residual confusion, lethargy, and cardiovascular strain; formal human plasma half-life is unverified.

EXTREME SUB-NANOMOLAR HAZARD (CB1 EC50 = 0.52 nM): Functional potency rivals 5F-MDMB-PINACA (50 ug active threshold); exceeding ~250–300 ug (0.25–0.30 mg) risks CDC-documented severe delirium, aggression, convulsions, and coma. Volumetric dilution is mandatory—never eyeball powder.

Quantitative Response Spectrum (Published Literature)

Third-person observational & toxicological brackets reported in scientific and harm-reduction literature — reference telemetry only, never consumption advice.

Threshold
15–35 ug (0.015–0.035 mg — tentative microgram estimate)
Cognitive & Sensory

Subtle shift in perception, mild relaxation, and slowed time sense.

Somatic & Autonomic

Slight heart-rate increase and faint dry mouth.

Light
35–75 ug (0.035–0.075 mg — tentative microgram estimate)
Cognitive & Sensory

Clear cannabimimetic mood elevation, sensory vividness, and calm detachment.

Somatic & Autonomic

Dry mouth, conjunctival redness, and warm limb heaviness.

Common Reference
75–150 ug (0.075–0.15 mg — tentative microgram estimate)
Cognitive & Sensory

Deep, heavy stone, pronounced time dilation, short-term memory suppression, and strong sedation.

Somatic & Autonomic

Marked tachycardia, ataxia, dizziness, and drowsiness.

Strong
150–300 ug (0.15–0.30 mg — tentative microgram estimate)
Cognitive & Sensory

Intense dissociation, disorientation, acute anxiety, hallucinations, and amnesia.

Somatic & Autonomic

Severe motor loss, vomiting, palpitations, tremors, and risk of abrupt stupor.

Heavy / Toxic Zone
300+ ug (0.30+ mg — tentative microgram estimate)
Cognitive & Sensory

Severe CDC-documented agitated delirium, aggression, acute psychosis, or deep coma.

Somatic & Autonomic

Seizures, severe cardiovascular instability, aspiration of vomit, respiratory depression, and death.

Interaction Matrix & Critical Contraindications

Critical Hazard — Never Combine

Alcohol, Opioids, Benzodiazepines, and GHB/GBL

Profound synergistic coma, airway loss during emesis, and fatal respiratory arrest.

Other Synthetic Cannabinoids (5F-MDMB-PINACA, ADB-FUBINACA, MDMB-4en-PINACA, ADB-BUTINACA)

Sub-nanomolar full CB1 stacking triggers immediate convulsions, delirium, and fatal cardiorespiratory toxicity.

Stimulants / Cathinones and Lithium

Extreme tachycardia, myocardial strain, severe delirium, and seizures.

Elevated Hazard — Avoid

Psychedelics, Dissociatives, and Tramadol

Provokes agitated delirium, psychotic panic, and lowered seizure threshold.

Caution / Receptor Attenuation

Botanical Cannabis

Never combine with or apply to cannabis flower; overrides THC's safety ceiling.

Structural Isomer & Sibling Comparison

ADB-PINACA (CB1 EC50 = 0.52 nM) is the 5-carbon pentyl homologue of ADB-BUTINACA (4-carbon butyl, EC50 = 6.36–11.5 nM) and alkyl counterpart of ADB-FUBINACA (4-fluorobenzyl, EC50 = 0.98–1.2 nM). That extra carbon makes ADB-PINACA >12-fold more potent at CB1 than ADB-BUTINACA, placing it alongside 5F-MDMB-PINACA (0.59 nM) as the most extreme microgram-active cannabinoid in our catalog.

Physicochemical Stability & Storage

Physical Form: White to off-white neat crystalline solid or powder (NEVER supplied on sprayed herbs). · Soluble in ethanol, methanol, DMF, and DMSO; practically insoluble in water.

Store tightly sealed in a cool, dry, light-resistant container.

Cross-Tolerance & Dependence Profile

Rapid CB1 downregulation, cross-tolerance with all cannabinoids, and severe physical/psychological withdrawal upon abrupt cessation of frequent use.

Codes on this card

Short meanings for the abbreviations printed with this substance.

Open the full glossary →
CB₁ / CB₂ Cannabinoid receptors CB1 and CB2

CB1 and CB2 are the two cannabinoid receptors named on these cards. Papers usually discuss CB1 in the nervous system and CB2 more often in immune tissue. The number beside them is often a Ki in nanomoles.

EC₅₀ / IC₅₀ Halfway concentration

EC50 is the concentration where a lab saw half of the maximum measured effect. IC50 is the concentration where it saw half of the maximum block. Smaller means that halfway point came at a lower concentration.

Kᵢ Binding tightness in nanomoles

Ki says how tightly a compound sits on a receptor in a binding test. It is written in nanomoles per litre. A Ki of 1 nM means very tight binding in that experiment.

ratio Selectivity ratio

A selectivity ratio divides two halfway numbers, such as SERT EC50 by DAT EC50, to show which target the assay reached first. The direction of the division has to be stated, or the number flips.

CAS CAS registry number

A CAS number is a passport number for one chemical entry in the CAS registry. The free base and a salt of the same parent usually have different CAS numbers.

IUPAC IUPAC Name & Molecular Formula

The molecular formula counts how many atoms of each element sit in one molecule, while the IUPAC name is the systematic map showing exactly how those atoms are connected.

CID / InChIKey PubChem CID & Standard InChIKey

PubChem CID is the catalog number in the U.S. National Library of Medicine chemistry database, and InChIKey is a 27-character digital fingerprint of the molecule's exact 3D structure.

1 mg / µg Calibrated Physical Form (1 mg Tablets, µg Liquid, Crystal)

Milligram-scale benzodiazepines are supplied as 1 mg tablets (1 tablet = 1 mg), microgram lysergamides as dissolved liquid (µg), and standard compounds as pure crystal or powder.

Comprehensive Analytical & Toxicological Monograph

ADB-PINACA (N-[(2S)-1-amino-3,3-dimethyl-1-oxobutan-2-yl]-1-pentyl-1H-indazole-3-carboxamide; CAS 1633766-73-0, PubChem CID 86280478) is a five-carbon pentyl-tailed indazole-3-carboxamide supplied strictly as a pure analytical crystalline solid or powder (`pure_powder_or_crystal`, C19H28N4O2, 344.46 g/mol — never sprayed onto herbs). In peer-reviewed fluorometric receptor profiling (Banister et al., 2015, PMID 26134475), ADB-PINACA acts as a sub-nanomolar full agonist at both human CB1 (EC50 = 0.52 nM) and CB2 receptors (EC50 = 0.88 nM), matching 5F-MDMB-PINACA (0.59 nM) at ~300 times the FLIPR potency of natural Delta9-THC (171 nM). Clinical emergency-medicine investigations by the CDC (Schwartz et al., 2015, PMID 25726258) linked ADB-PINACA exposure to outbreaks of severe delirium, aggression, anxiety, and hospitalizations. Because no safe clinical human dose exists and a single 1 mg powder grain contains multiple heavy exposures, strict volumetric liquid dilution is mandatory: tentative inhaled microgram brackets place threshold activity at 15–35 ug, light effects at 35–75 ug, common heavy cannabimimetic sedation at 75–150 ug, strong dissociation and emesis at 150–300 ug, and life-threatening delirium, convulsions, and coma above 300 ug (0.30 mg). Inhaled effects begin within minutes across an estimated 1–2.5 hour arc, with residual confusion lasting hours longer. Compared to 4-carbon sibling ADB-BUTINACA (EC50 6.36–11.5 nM), ADB-PINACA is >12-fold more potent and far less forgiving; it is also roughly twice as potent at CB1 as 4-fluorobenzyl sibling ADB-FUBINACA (EC50 0.98–1.2 nM). Never combine with alcohol, opioids, benzodiazepines, GHB/GBL, other cannabinoids, stimulants, psychedelics, or lithium.

Chemical Architecture & Structural Profile

ADB-PINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentylindazole-3-carboxamide) is a reference compound belonging to the Cannabinoids (Indazole carboxamides) class, characterized by the molecular formula C19H28N4O2 and a molar mass of 344.5 g/mol. The parent molecule is indexed under CAS registry number 1633766-73-0 and in the NCBI PubChem database as CID 86280478 (Standard InChIKey: FWTARAXQGJRQKN-UHFFFAOYSA-N).

Citations

Reference Toxicology & Safety Profile

In documented chemical and harm-reduction literature (PubChem / PsychonautWiki, CC BY 4.0), ADB-PINACA is indexed within the Cannabinoids (Indazole carboxamides) structural group. Synthetic indazole carboxamide exhibiting high receptor affinity in in-vitro assays; requires calibrated micro-analytical balances and full dermal and respiratory protection. Standard laboratory handling precautions—including nitrile gloves, eye protection, and local exhaust ventilation—apply whenever handling the reference material.

Citations

Analytical Use & Laboratory Notice

This reference sheet provides chemical, analytical, and toxicological provenance only. The material is strictly not for human consumption, diagnostic, or veterinary use. Research-use labelling does not establish legal status in any jurisdiction.

Citations